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Abstract
Background: Most available pharmacotherapies for alcohol-dependent patients target abstinence; however,
reduced alcohol consumption may be a more realistic goal. Using randomized clinical trial (RCT) data, a previous
microsimulation model evaluated the clinical relevance of reduced consumption in terms of avoided alcohol-
attributable events. Using real-life observational data, the current analysis aimed to adapt the model and confirm
previous findings about the clinical relevance of reduced alcohol consumption.
Methods: Based on the prospective observational CONTROL study, evaluating daily alcohol consumption among
alcohol-dependent patients, the model predicted the probability of drinking any alcohol during a given day.
Predicted daily alcohol consumption was simulated in a hypothetical sample of 200,000 patients observed over a
year. Individual total alcohol consumption (TAC) and number of heavy drinking days (HDD) were derived. Using
published risk equations, probabilities of alcohol-attributable adverse health events (e.g., hospitalizations or death)
corresponding to simulated consumptions were computed, and aggregated for categories of patients defined by
HDDs and TAC (expressed per 100,000 patient-years). Sensitivity analyses tested model robustness.
Results: Shifting from >220 HDDs per year to 120–140 HDDs and shifting from 36,000-39,000 g TAC per year
(120–130 g/day) to 15,000–18,000 g TAC per year (50–60 g/day) impacted substantially on the incidence of events
(14,588 and 6148 events avoided per 100,000 patient-years, respectively). Results were robust to sensitivity analyses.
Conclusions: This study corroborates the previous microsimulation modeling approach and, using real-life data,
confirms RCT-based findings that reduced alcohol consumption is a relevant objective for consideration in alcohol
dependence management to improve public health.
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Background
Alcohol dependence is a chronic disease, characterized by
craving, tolerance, a preoccupation with alcohol, and con-
tinued drinking in spite of harmful consequences [1, 2].
The prevalence of alcohol dependence was recently esti-
mated to be 5–6 % in men and around 2 % in women in
Europe [3, 4]. For the same region, alcohol dependence
was found to be responsible for 8.4 % of premature deaths,
10.7 % in men and 3.7 % in women [5]. In addition to con-
ditions wholly attributable to alcohol (e.g., alcoholic liver
cirrhosis or alcoholic gastritis), alcohol is a contributory
cause for many other diseases (e.g., various forms of
cancer or cardiovascular disease, or epilepsy) and almost
all forms of injuries [6]. The World Health Organization
(WHO) recently reported that alcohol consumption was
identified as an important risk factor for more than 60 dif-
ferent major disorders or injuries [7]. Another recent
systematic literature review corroborated the causal im-
pact of average alcohol consumption volume for these
conditions and added systematic evidence for infectious
disease categories such as tuberculosis or pneumonia [8].
Alcohol dependence represents a significant burden
for European healthcare systems and society. A recent
literature review on the economic burden pertaining to
alcohol dependence in Europe showed that the direct
costs were substantial (annual total direct costs ranging
from €1 billion to €7.8 billion in [2012 Euros] depending
on the country), primarily driven by hospitalization [9].
Indirect costs were even more substantial than direct
costs (€68 billion at the European level).
Standard treatment for patients with alcohol depend-
ence is based upon detoxification and rehabilitation,
with the aim of halting alcohol consumption, main-
taining abstinence, preventing the complications of
chronic and excessive alcohol use, and managing the
symptoms of alcohol withdrawal. Treatment mainly
comprises psychosocial support, such as motivational
interviewing or structured recovery programs [10].
Pharmacological intervention may be used in combination
with psychosocial support, but currently not in the major-
ity of treatment [10]. Current pharmacological strategies
for managing alcohol dependence generally target abstin-
ence and comprise aversive medications (e.g., disulfiram),
which produce an unpleasant reaction to alcohol that
deters the patient from drinking, and anti-craving medica-
tions (e.g., naltrexone, acamprosate), which reduce the
patient’s desire to drink and aim for relapse prevention
and maintained abstinence [10].
However, less than 10 % of patients with alcohol de-
pendence are treated [11]. In England, only about 6 % of
the 1 million people per year aged 16 to 65 years who
are alcohol dependent receive treatment [12]. For many
patients not able or willing to achieve abstinence immedi-
ately, reduced consumption may be a more realistic goal.
Indeed, low-risk drinking, or reduction of daily consump-
tion, has become an accepted treatment goal in many
treatment settings and for many patients with alcohol de-
pendence [3, 13, 14]. In 2013, the European Medicines
Agency granted marketing authorization for nalmefene
for the reduction of alcohol consumption in adult patients
with alcohol dependence; nalmefene should only be
prescribed in conjunction with continuous psychosocial
support focused on treatment adherence and reducing
alcohol consumption [15].
A recently published microsimulation model evaluated
the clinical relevance of reducing alcohol consumption
in terms of alcohol-attributable diseases or injuries
avoided [16]. In this study, alcohol consumption simula-
tion was based on pooled data from three pivotal ran-
domized clinical trials (RCTs) comparing the efficacy
and safety of as-needed nalmefene 18 mg versus placebo
in reducing alcohol consumption in patients with alcohol
dependence [17–20]. However, the population from
nalmefene RCTs was selected according to specific inclu-
sion/exclusion criteria, and may not be representative of
all patients with alcohol dependence in routine clinical
practice. Moreover, the timeframe considered was limited
(24 or 52 weeks) [17–20]. As there is evidence from previ-
ous studies that alcohol consumption levels vary over time
[21–23], and that the incidence of diseases, injuries and
subsequent mortality is related to average alcohol con-
sumption and the variability of consumption over time
[24, 25], performing a similar analysis using data from an
observational study, representative of daily clinical prac-
tice, with longer follow-up (up to 487 days) was deemed
important to confirm the external validity of the previous
findings.
The objective of this analysis was to adapt the previ-
ously published microsimulation model [16], using data
collected in an observational setting, and to determine
whether this adapted version corroborated findings from
the previous model about the clinical relevance of redu-
cing alcohol consumption in terms of alcohol-attributable
diseases or injuries avoided.
Methods
Data source
The CONTROL (COhort oN TReatments of alcohOL
dependence) study is a single center, prospective, ob-
servational study evaluating consecutive patients with
alcohol dependence assessed for the first time at the
Alcohol Treatment Center at Lausanne University
Hospital, Lausanne, Switzerland. CONTROL included
143 participants, followed for up to 487 days. Full de-
tails of the CONTROL study design have been published
previously [26, 27]. The primary objective of CONTROL
was to describe the drinking patterns of patients with
alcohol dependence and their baseline predictive factors
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during a 12-month period. More specifically, it intended
to describe the population of patients with alcohol de-
pendence, their disease management and their evolution
in terms of alcohol consumption, social consequences,
quality of life and resource use, after an initial evaluation
for alcohol treatment [26].
All eligible patients suspected of experiencing alco-
hol dependence were included in the study. Regular
visits were planned at the unit for assessments. Pa-
tients were free to choose their drinking objective, and
treatment provided included a combination of motiv-
ational interviewing, relapse prevention measures and
pharmacotherapy [26].
Model overview
The predictive microsimulation model used for the
current analysis has been described in detail elsewhere
[16]. This model, using available individual data from
CONTROL, simulated the daily alcohol consumption of
individual patients for a 12-month time period, based on
statistical equations obtained by regression analysis. As
the model described herein used data available from the
CONTROL study and did not involve any additional
intervention or data collection, ethical approval and
patient consent were not required. Model outcomes
included short-term and long-term events. Short-term
events include alcohol-attributable diseases or injuries in-
curred from a single episode of alcohol consumption. The
probabilities of such events were modelled day by day.
These events included transport-related injuries [28, 29],
non-transport-related injuries [28, 29], ischemic stroke [30],
and ischemic heart disease [31, 32]. Long-term events in-
cluded alcohol-attributable diseases associated with average
alcohol consumption over extended periods of time. The
probabilities of such events were estimated as functions of
average consumption over 1 to 6 months, depending on
the physiopathology of the disease. These events included
liver cirrhosis [8], acute and chronic pancreatitis [33],
pneumonia [34], and hemorrhagic stroke [30]. Cancer out-
comes were excluded because, even though alcohol is an
established carcinogen [35], the timeframe to develop
alcohol-attributable cancer is too long [36].
Alcohol consumption simulation
Data from CONTROL were used to obtain predictive
statistical equations for daily alcohol consumption. A
two-part model was used in which it was implicit that
the amount of alcohol consumed over 1 day resulted
from a combination of the decision to drink or not over
that day, and the consumed amount (in grams), which
was conditional upon drinking any alcohol. The first
equation predicted the probability of drinking any alcohol
over 1 day; it was obtained using logistic regression. The
second equation predicted the quantity of alcohol
consumed over 1 day, conditional upon drinking any
alcohol over that day, using a generalized mixed model
with logarithm link, and assuming that the quantity of al-
cohol consumed in grams has a negative binomial distri-
bution. Random effects by patients were introduced in the
statistical model to account for the dependence between
probabilities of drinking and consumed amounts on differ-
ent days within patients.
Predictive variables were selected among patient char-
acteristics identified as influencing alcohol consumption
in terms of drinking level and pattern of drinking, such
as age, gender, depressive status at baseline, mean and
standard deviation of daily alcohol consumption during
the month before baseline, or the type of treatment after
the baseline visit. In addition, the day of the week was
considered to be a relevant covariate, as individuals tend
to consume more alcohol on Fridays and Saturdays [37].
Consumption on previous days was also included as a
predictive variable of daily alcohol consumption: log-
transformed values of alcohol consumption the day
before, 2 days before and 7 days before, as being signifi-
cant predictors.
Statistical equations were used to simulate the daily
alcohol consumption of 200,000 patients over a year,
taking into account estimated regression coefficients as
well as residual standard errors and patient random effects.
Patient profiles at baseline (age, sex, depression status,
mean daily consumption, standard deviation of daily con-
sumption) were drawn randomly from CONTROL data.
Several endpoints were derived from daily alcohol con-
sumptions. In 2010, the European Medicines Agency
(EMA) recommended alcohol dependence treatment
strategies for harm reduction approach to be expressed
by the reduction in total alcohol consumption (TAC)
and in the number of heavy drinking days (HDD, de-
fined as a day with alcohol consumption >60 g of pure
alcohol for men and >40 g for women).
Disease events
The microsimulation model outcomes were numbers of
finished consultant episodes (FCEs), i.e., inpatient episodes
under the responsibility of one consultant, before transfer
or discharge, for alcohol-attributable events. These were
used as a proxy for the number of diagnoses of alcohol-
attributable diseases or injuries requiring hospitalization.
Two components were used to simulate probabilities of
events: a general population risk and relative risks depend-
ing on alcohol consumption level.
To allow comparison with previous findings, the gen-
eral population risk in this analysis was taken from the
Hospital Episodes Statistics of England [38], using num-
bers of FCEs. An implication of using the number of
FCEs is that cases diagnosed with a disease potentially
related to alcohol consumption are taken into account
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even if this disease is not the cause of initial admission.
Relative risks, at a given level of alcohol, were based on
several published meta-analyses [8, 29–34, 39]. Those
functions were estimated by pooling the results of iden-
tified epidemiological studies assessing the impact of
alcohol consumption and were developed by the Center
for Addiction and Mental Health (Toronto, Ontario,
Canada). Risk ratios were expressed as continuous func-
tions of consumption (g/day), average daily consumption
over the previous month, or average daily consumption
over the previous 6 months.
Different types of functions were used, including non-
linear exponential functions (transport injuries, injuries
other than transport, liver cirrhosis, acute and chronic
pancreatitis, pneumonia and hemorrhagic stroke), or
step functions (ischemic heart disease and ischemic
stroke). When relevant, capping was used on alcohol
consumption.
Statistical analysis
Probabilities of events (daily probabilities for ischemic
heart disease, ischemic stroke, traffic injuries and other in-
juries, monthly probabilities for pneumonia, or 6-monthly
probabilities for cirrhosis, pancreatitis and hemorrhagic
stroke) for each patient were summed over 12 months
and then aggregated over groups of patients defined by
the number of HDDs and TAC across 12 months. In order
to mitigate gender differences in risk of events and the fact
that the repartition of men and women in HDD or
TAC categories varies, analysis was performed for
men and women separately and results were then
combined based on the proportions of males and
females in the CONTROL cohort (63.64 and 36.36 %,
respectively).
First, deterministic sensitivity analyses were undertaken,
to assess the impact of errors around parameters of rela-
tive risk functions, as found in the literature. The analyses
were performed using the lower limit of variance of all
relative risk function parameters with statistical uncer-
tainty simultaneously, and then the upper limit of variance
of all such parameters simultaneously. Probabilistic ana-
lyses were then performed, to assess uncertainty around
alcohol consumption simulation. Each parameter of the
logistic and negative binomial regression models was
assumed to be normally distributed since they were
maximum likelihood estimates. Two hundred sets of
random parameters of the model were simulated; for
each set of parameters, the alcohol consumption of 1000
patients was simulated in addition to their alcohol-
attributable events, resulting in a total of 200,000 patients
simulated. Confidence intervals around the number of
simulated events were computed by extracting 2.5th and
97.5th percentiles among simulations, for all patients
(male and female).
Results
Alcohol consumption
In the CONTROL cohort, the mean alcohol consump-
tion was 22.16 g/day (SD 48.45, range 0–640) over the
complete (up to 487 days) study follow-up (35,545
patient-days). An average of 190.15 days (SD 124.59,
range 1–487) of follow-up was used to estimate statis-
tical equations predicting the probability of drinking and
the amount of alcohol consumption (g) The estimated
parameters of the statistical equations are presented in
Table 1.
Model to estimate the probability of drinking
The model for the probability of drinking was estimated
based on 31,230 available patient-days, of which 9752
were drinking days. On the reference patient-day (male
patient, who did not previously receive any form of al-
cohol dependence treatment, not currently receiving
pharmacological treatment for alcohol dependence, not
depressed, on a Saturday, with all continuous factors
equal to 0), the probability of drinking was 2.90 %.
Positive coefficients imply a higher probability to have
at least one drink over 1 day (Table 1). For example,
consumption on previous days and on the same day of
the previous week were associated with an increased
probability of drinking. The probability of drinking
increased by 0.05 % everyday throughout the simulated
1-year period.
Model to predict the amount of alcohol
The negative binomial model for the amount of alcohol
consumed on drinking days was estimated based on data
describing the 9752 drinking days. For a reference
patient-day, the mean quantity of alcohol consumed was
39.11 g. Conditional upon drinking, the mean quantity
of alcohol consumed on drinking days increased with
consumption on the previous days and on the same day
of the previous week (Table 1).
Clinical relevance of a reduction in the number of Heavy
Drinking Days (HDDs) per year
The number of HDDs over 1 year was divided into eight
categories with a range of 20 HDDs/year, roughly corre-
sponding to 2 monthly HDDs [16]. Table 2 presents the
distribution of simulated consumptions in HDD categor-
ies, as well as the number of disease events per 100,000
patients for each event, for males and females combined.
Most of the 200,000 simulated patients had fewer than
100 HDDs/year (83.5 %). Another 9.2 % had between
100 and 220 HDDs, and the remaining patients (7.3 %)
had more than 220 HDDs.
Using a similar approach to François et al. [16], a
shift from the category >220 HDDs/year to the cat-
egory 120–140 HDDs/year among 100,000 patients
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Table 1 Coefficients of two-part model for alcohol consumption prediction
Logistic regression model for probability of drinking Negative binomial regression model for amount of alcohol consumed on
drinking days
Parameter Level Estimate Standard error P-value Odds ratio Estimate Standard error P-value Odds ratio
Intercept −3.5123a 0.6325 <.0001 - 3.6665b 0.2766 <.0001 -
Age (years, ref = 0) 0.006217 0.01127 0.5813 1.0062 −0.01163 0.004807 0.0156 0.9884
Sex (ref = male) Female 0.2055 0.2796 0.4624 1.2281 0.01766 0.1221 0.885 1.0178
Day (ref = Saturday) Sunday −0.05629 0.08452 0.5054 0.9453 −0.02609 0.01826 0.153 0.9742
Monday −0.4179 0.0839 <.0001 0.6584 −0.05914 0.01834 0.0013 0.9426
Tuesday −0.2794 0.08356 0.0008 0.7562 −0.0489 0.01838 0.0078 0.9523
Wednesday −0.2098 0.08446 0.013 0.8107 −0.03008 0.01845 0.103 0.9704
Thursday −0.05853 0.08508 0.4915 0.9431 −0.02463 0.01856 0.1846 0.9757
Friday −0.03683 0.08563 0.6671 0.9638 0.004004 0.01865 0.83 1.004
Log (1 + consumption) day −1 0.5019 0.01368 <.0001 1.6519 0.07999 0.004127 <.0001 1.0833
Log (1 + consumption) day −2 0.361 0.01396 <.0001 1.4348 0.05808 0.00408 <.0001 1.0598
Log (1 + consumption) day −7 0.3777 0.01312 <.0001 1.4589 0.05105 0.003695 <.0001 1.0524
Treatment during follow-up (ref = No treatment) Psychological −0.1548 0.324 0.6328 0.8566 0.1968 0.1405 0.1615 1.2175
Psychological and
pharmaceutical
−0.07805 0.58 0.893 0.9249 0.09311 0.2426 0.7012 1.0976
Time index 0.000461 0.000198 0.02 1.0005 0.02279 0.005067 <.0001 1.0231
Mean of baseline consumption per patient 0.000659 0.001405 0.6389 1.0007 0.01156 0.006173 0.061 1.0116
Standard deviation of baseline consumption
per patient
0.00031 0.003629 0.9319 1.0003 0.0253 0.0153 0.0982 1.0256
Depressed (ref = No) Yes −0.1817 0.2674 0.4968 0.8339 0.1539 0.1148 0.1801 1.1664
Day 1 −3.9724 0.5882 <.0001 0.0188 −0.09164 0.1547 0.5537 0.9124
Day 2 −2.5372 0.5816 <.0001 0.0791 −0.1644 0.1721 0.3393 0.8484
Day 3 −0.475 0.386 0.2185 0.6219 −0.2108 0.1105 0.0565 0.8099
Day 4 −0.2679 0.4006 0.5036 0.765 −0.1374 0.1088 0.2067 0.8716
Day 5 −0.6315 0.4465 0.1573 0.5318 −0.3298 0.1207 0.0063 0.7191
Day 6 −1.0807 0.5291 0.0411 0.3394 −0.2246 0.1489 0.1314 0.7988
Day 7 −0.4915 0.5832 0.3994 0.6117 −0.2601 0.1488 0.0805 0.771
aThe intercept estimate of the logistic regression is the coefficient from which the probability of drinking can be derived for the reference patient-day. On the reference patient-day, the probability of drinking
is p = exp(3.5123/(1 + exp(3.5123)) = 0.0290
bThe intercept estimate of the negative binomial model is the coefficient from which the mean amount of alcohol consumed can be derived for the reference patient-day. On the reference patient-day, the mean
quantity of alcohol consumed, in grams, is c = exp(3.6665) = 39.11
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was predicted to avoid 702 (95 % CI [698;707])
events of ischemic heart disease, 234 (95 % CI
[233;236]) events of ischemic stroke, 728 (95 % CI
[722;734]) events of transport-related injuries, 3359
(95 % CI [3338;3381]) events of non-transport re-
lated injuries, 1622 (95 % CI [1584;1660]) events of
liver cirrhosis, 4239 (95 % CI [4044;4433]) events of
pancreatitis, 1032 (95 % CI [1015;1049]) events of pneu-
monia, and 296 (95 % CI [287;304]) events of
hemorrhagic stroke.
Clinical relevance of a reduction in total alcohol
consumption (TAC) per year
TAC/year was divided into ten categories with a range
of 3000 g/year, roughly corresponding to 1 standard
drink/day (10 g/day) [16]. As above, Table 3 presents the
distribution of simulated consumptions in TAC categories,
as well as the number of disease events per 100,000
patients for each event, for each class of TAC/year, for
males and females combined.
Most of the 200,000 simulated patients had a TAC
below 15,000 g/year (84.4 %). Another 10.8 % had a TAC
between 15,000 g and 39,000 g, and the remaining
patients (4.6 %) had a TAC above 39,000 g.
Using a similar approach to François et al. [16], a shift
from the category 36,000–39,000 g TAC/year to the cat-
egory 15,000–18,000 g TAC/year among 100,000 pa-
tients was predicted to avoid 588 (95 % CI [565;612])
events of ischemic heart disease, 173 (95 % CI [161;184])
events of ischemic stroke, 518 (95 % CI [498;538]) events
of transport-related injuries, 2388 (95 % CI [2244;2533])
events of non-transport related injuries, 555 (95 % CI
[541;568]) events of liver cirrhosis, 737 (95 % CI
[672;803]) events of pancreatitis, 537 (95 % CI [520;556])
events of pneumonia and 155 (95 % CI [144;164]) events
of hemorrhagic stroke.
Sensitivity analyses
Deterministic sensitivity analyses on parameters of rela-
tive risk functions showed that the interval between
Table 2 Number of events per 100,000 patient-years by HDD categorya
HDDs per year (days) Ischemic heart
disease
Ischemic
stroke
Traffic
injuries
Other
injuries
Cirrhosis Pancreatitis Pneumonia Hemorrhagic
stroke
Total
<100 1170 382 40 834 153 105 1517 107 4308
100–120 1727 554 269 3047 380 384 1813 156 8330
120–140 1841 591 326 3486 461 530 1889 182 9306
140–160 1946 625 390 3904 549 710 1965 209 10298
160–180 2027 652 471 4262 716 1304 2060 226 11718
180–200 2079 672 604 4590 914 1666 2222 251 12998
200–220 2152 697 720 4993 1244 2643 2398 287 15134
>220 2543 825 1054 6845 2083 4769 2921 478 21518
aOut of the 200,000 patients simulated, 83.5 % had fewer than 100 HDDs/year, 9.2 % had between 100 and 220 HDDs, and 7.3 % had more than 220 HDDs. For
each HDD group of patients, the probabilities of events for each patient were summed over 12 months, and this sum was transformed to represent the number
of events per 100,000 individuals
Table 3 Number of events per 100,000 patient-years by TAC categorya
TAC per year (×1000 g) Ischemic heart
disease
Ischemic
stroke
Traffic
injuries
Other
injuries
Cirrhosis Pancreatitis Pneumonia Hemorrhagic
stroke
Total
<15 1173 383 42 853 150 95 1516 106 4318
15–18 1796 584 301 3401 329 139 1825 149 8524
18–21 1964 639 368 4025 377 158 1885 162 9578
21–24 2070 676 459 4471 431 189 1947 175 10418
24–27 2080 685 590 4661 520 282 2072 193 11083
27–30 2179 723 680 5158 605 390 2175 210 12120
30–33 2273 750 741 5527 683 491 2239 228 12932
33–36 2357 752 768 5663 772 656 2293 267 13528
36–39 2384 757 819 5789 884 876 2362 304 14175
>39 2483 812 1170 7031 3173 8224 3551 817 27261
aOut of the 200,000 patients simulated, 84.4 % had a TAC below 15,000 g/year, 10.8 % had a TAC between 15,000 and 39,000 g/year, and 4.6 % had more than
39,000 g/year. For each TAC group of patients, the probabilities of events for each patient were summed over 12 months, and this sum was transformed to
represent the number of events per 100,000 individuals
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minimum and maximum values increased in categories
with higher HDDs or higher TAC for all diseases and in-
juries (Additional file 1: Table S1a and S1b). The total
number of disease events avoided for a difference in
the number of HDDs between 120–140 days/year and
100–120 days/year varied from 556 to 1687 per
100,000 person-years, for all events combined. In the
same way, the total number of disease events avoided
for a difference in TAC between 36,000–39,000 and
33,000–36,000 per year varied from 353 to 1191 per
100,000 person-years, for all events combined.
Probabilistic sensitivity analyses of the uncertainty
around parameter estimates from the logistic and nega-
tive binomial models provided 95 % confidence intervals
(Additional file 2: Table S2a and S2b) around the num-
ber of events in each HDD and TAC category. The total
number of events avoided for a difference in HDD be-
tween 120–140 days and 100–120 days varied from 668
to 1091 per 100,000 person-years, for all events com-
bined. The difference in number of events avoided corre-
sponding to a lowering of TAC from 36,000–39,000 to
33,000–36,000 g/year varied from 705 to 896 per 100,000
person year for all events combined. These values are
within acceptable ranges of variability, demonstrating the
relatively low uncertainty around parameter estimates
from the logistic and negative binomial models resulting
from the statistical power provided with the number of
patient-days and the number of patient-drinking days.
Discussion
As observed in the previous model [16], the present
microsimulation model predicted that a decrease in the
number of HDDs/year by 20 was associated with consid-
erable differences in terms of harmful events avoided.
Similarly, a 3000 g/year decrease in TAC (i.e., approx. a
standard drink/day) was predicted to lead to a substan-
tial decrease in the incidence of harmful events. Even in
the low-case scenario, the number of events avoided re-
mains clinically important and confirms the base-case
results. Abstinence has been preferred as the treatment
goal in the management of alcohol-dependence [40, 41].
Alcohol consumption reduction is now recommended
by the EMA as a valuable treatment option to reduce
alcohol-attributable burden, and attracts patients who
are still untreated. From the clinical perspective, this
model could then be a useful tool to assess and compare
the public health impact of alternative strategies to man-
age alcohol dependence. For example, a small reduction
in alcohol consumption, from 100 to 90 g/day, in six
male patients would be equivalent to achieving abstin-
ence in one male patient in terms of reduction of the
incidence of liver cirrhosis. Given that abstinence is a
difficult goal to achieve, alcohol consumption reduction
could contribute significantly to reducing the burden of
alcohol dependence, with a potentially large positive
impact from the public health perspective.
Modeling seemed to be a reasonable approach for this
type of investigation. Although it would have been theoret-
ically possible to conduct an observational study, a very
large number of patients and a large timeframe would have
been required to obtain such precision. Moreover, this
model makes it possible to use and combine information
from several previous studies related to the risk of injury
and disease associated with alcohol consumption. The
model takes into account the relative risk of different events
over different time periods (1 day, 1 month or 6 months) in
accordance with the clinical occurrence and physiopathol-
ogy of each event.
Another study using this microsimulation model was
published previously [16]. The same methodology was
used in the present study, in terms of alcohol consump-
tion simulation (two-part model), and event prediction
(general population risks and risk ratios depending on
level of alcohol consumption). However, in the present
study, an observational study dataset was used to predict
alcohol consumption instead of data from RCTs. Results
of the two approaches are generally consistent, although
the number of events is slightly higher in the present
study, likely to be due to a higher variability in alcohol
consumption simulations and the fact that the patient
population in the current model was not selected on the
basis of exclusive RCT criteria; indeed, the patient popu-
lation in the current study (based on the CONTROL
cohort) represents the full range of severity of alcohol
dependence. Consistently, the incidence of events gener-
ally increases with TAC and number of HDDs. As the
same risk equations were used in both studies, most of
the results for number of events are similar when com-
pared by category (e.g., 2027 cases of ischemic heart
disease in the present study vs. 1928 in the previous
study for the category 160–180 HDDs/year, over
200,000 patients). Small differences are due to the het-
erogeneity of drinking patterns among the category of
selected patients. Only the number of events in the
lowest- and highest-consumption categories are largely
different (e.g., 1170 ischemic heart disease events in the
present study vs. 1563 in the previous study for the cat-
egory <100 HDDs/year, over 200,000 patients). Patients
from CONTROL and those from the nalmefene RCTs
differ: the range of alcohol consumption is much higher
in CONTROL, with more patients drinking very rarely
or with very high consumption levels. Again, differ-
ences for the upper range probably reflect the fact that
the patient population in the current study represents
the entire range of alcohol dependence severity (com-
pared with that in RCTs); for the lowest range, differ-
ences reflect a higher rate of abstinence in patients
with severe alcohol dependence (based on CONTROL)
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whereas, in the nalmefene RCTs, the approach was
focused on alcohol consumption reduction. Thus, it
seems reasonable to find higher numbers of events in
the highest categories, and smaller numbers in the low-
est categories. As in François et al. [16], although the
sensitivity analyses revealed a significant variation in
number of events by consumption category, justified
by the use of extreme scenarios, the number of events
avoided when shifting category is stable. Overall, based
on the comparison between observations (as reported
in François et al. [16]) and simulations in alcohol con-
sumption averages, the approach was found to be valid
and confirms the robustness of the model.
In a few instances, the numbers of events predicted
for the highest TAC categories were lower than the
numbers predicted for immediately lower categories.
These counter-intuitive results occurred for two reasons.
First, some relative risk functions were assumed to reach
a plateau above some level of consumption (e.g., func-
tions for ischemic stroke and ischemic heart disease).
Secondly, the numbers of patients simulated in higher
categories of TAC were small, so that sampling vari-
ability around numbers of events predicted in those
categories was large.
This model uses relative risk functions obtained from
the literature. A limitation is that some relative risk
functions were developed using a low number of points
(such as the one used for pancreatitis [33]). Conse-
quently, there is uncertainty around the shapes of the
curves. In particular, the relative risk progression for
very high consumption levels is highly dependent on as-
sumptions used for extrapolating those curves. Another
limitation is that many studies used to estimate those
functions were not conducted in individuals with alcohol
dependence. However, it is possible that the risk of acci-
dent, for example, does not increase with consumption
over 1 day in individuals with alcohol dependence as
much as in the general population. Furthermore, most
studies evaluating the relationship between alcohol
consumption and the incidence of diseases are cross-
sectional studies showing that patients consuming more
alcohol have a greater risk of disease, but they do not
show when the risk of disease starts decreasing after a
reduction in consumption. Thresholds for the clinical
relevance of decreased or increased alcohol consumption
could be different. For some events, decreasing alcohol
consumption may have a direct effect while, for others,
the risk might take longer to change.
This microsimulation model does not integrate memory
of past events: future events do not depend on prior
events. This simplification may lead to potentially inaccur-
ate predictions. For example, a disabled patient following
a stroke may not be able to drive, and therefore is unlikely
to have a traffic accident. Thus, it would be appropriate to
reduce the risk of a traffic accident following a stroke. It is
also possible that the occurrence of an event increases the
risk of having another event. The impact of this simplifica-
tion is thought to be quite small in this analysis over 1 year,
since probabilities of events over this timeframe are rela-
tively low. However, in an extrapolation over several years,
this could be a more important limitation. Relaxing this
assumption would require a considerably more complex
structure, and obtaining the data to populate such a model
would also pose a great challenge.
Finally, it is noteworthy that the general population
risks were United Kingdom-specific, whereas alcohol
consumption was based on data from Swiss patients. Al-
though differences in distribution categories can be
found between countries, due to different consumption
patterns, little impact is expected regarding differences
in the number of events between categories.
An external validation of the model was also performed,
demonstrating that these model outputs were higher than
existing published evidence. This is not reported in this
publication, but values used for comparison are avail-
able in François et al. [16]. For example, considering
hemorrhagic strokes in a population drinking over
60 g/day (18,000–24,000 TAC/year category), the
model predicted about 160 events, while Reynolds et
al. predicted about 126 [42]. Nevertheless, the compar-
ability of our results and those in the wider literature may
be questioned, because definitions of events may differ
(e.g., in terms of diagnostic codes used), populations were
not fully similar, and many studies considered alcohol
consumption as a categorical variable.
Conclusions
This analysis, based on a microsimulation model popu-
lated with data from an observational study, confirms
findings about the clinical relevance of reducing alcohol
consumption in terms of alcohol-attributable diseases or
injuries avoided. The risk of experiencing ischemic heart
disease, ischemic stroke, traffic-related injuries, non-
traffic-related injuries, cirrhosis, pancreatitis, pneumonia
and hemorrhagic stroke in patients with alcohol depend-
ence has been shown to be substantially larger in
patients with more HDDs/year or greater TAC/year. A
HDD difference of 20 HDDs/year, or a TAC difference
of 3000 g/year (approx. one standard drink/day), was
demonstrated to have a substantial impact on the inci-
dence of these harmful events. The results were robust
to sensitivity analysis and validated by external data
sources. Thus, reduced alcohol consumption, in terms of
HDDs or TAC, appears to be a relevant objective for
consideration in alcohol dependence management.
Moreover, this study contributes to the validation of the
microsimulation model, which appears to provide sound
estimates of the changes in the incidence of diseases and
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injuries associated with modifications in alcohol consump-
tion profiles in a population of alcohol-dependent individ-
uals. This microsimulation model could be a useful tool to
assess the public health impact, budget impact, or cost-
effectiveness of alternative interventions to manage alcohol
dependence.
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